Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. (Abstract)

Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes and early-to-moderate diabetic kidney disease.In a double-blind trial, we randomly assigned participants with type 1 diabetes, a serum urate level of at least 4.5 mg per deciliter (...) , an estimated GFR of 40.0 to 99.9 ml per minute per 1.73 m2 of body-surface area, and evidence of diabetic kidney disease to receive allopurinol or placebo. The primary outcome was the baseline-adjusted GFR, as measured with iohexol, after 3 years plus a 2-month washout period. Secondary outcomes included the decrease in the iohexol-based GFR per year and the urinary albumin excretion rate after washout. Safety was also assessed.A total of 267 patients were assigned to receive allopurinol and 263 to receive

2020 NEJM

2. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. (Abstract)

Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. Continuous glucose monitoring (CGM) provides real-time assessment of glucose levels and may be beneficial in reducing hypoglycemia in older adults with type 1 diabetes.To determine whether CGM is effective in reducing hypoglycemia compared with standard blood glucose monitoring (BGM) in older adults with type 1 diabetes.Randomized clinical trial conducted at 22 (...) ); and cognition and patient-reported outcomes, with adjustment for multiple comparisons to control for false-discovery rate.Of the 203 participants (median age, 68 [interquartile range {IQR}, 65-71] years; median type 1 diabetes duration, 36 [IQR, 25-48] years; 52% female; 53% insulin pump use; mean HbA1c, 7.5% [SD, 0.9%]), 83% used CGM at least 6 days per week during month 6. Median time with glucose levels less than 70 mg/dL was 5.1% (73 minutes per day) at baseline and 2.7% (39 minutes per day) during

2020 JAMA

3. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. (Abstract)

Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. Adolescents and young adults with type 1 diabetes exhibit the worst glycemic control among individuals with type 1 diabetes across the lifespan. Although continuous glucose monitoring (CGM) has been shown to improve glycemic control in adults, its benefit in adolescents and young adults has not been demonstrated.To determine the effect of CGM on glycemic (...) control in adolescents and young adults with type 1 diabetes.Randomized clinical trial conducted between January 2018 and May 2019 at 14 endocrinology practices in the US including 153 individuals aged 14 to 24 years with type 1 diabetes and screening hemoglobin A1c (HbA1c) of 7.5% to 10.9%.Participants were randomized 1:1 to undergo CGM (CGM group; n = 74) or usual care using a blood glucose meter for glucose monitoring (blood glucose monitoring [BGM] group; n = 79).The primary outcome was change

2020 JAMA

4. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association

Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site (...) uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association , MD, MHA, Chair , MD, MPH, FAHA, Vice Chair , MD, FAHA , MD , MD , MD , MD, FAHA , MD, FAHA , MD, MHS , MD, MPH, FAHA , MD, FAHA Suzanne V. Arnold , Deepak L. Bhatt , Gregory W. Barsness , Alexis L

2020 American Heart Association

5. The effects of a supportive-educational intervention on women with type 2 diabetes and diabetic peripheral neuropathy: a randomized controlled trial

The effects of a supportive-educational intervention on women with type 2 diabetes and diabetic peripheral neuropathy: a randomized controlled trial The Effects of a Supportive-Educational Intervention on Women With Type 2 Diabetes and Diabetic Peripheral Neuropathy: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions . 2020 Jun;34(6):794-802. doi: 10.1177/0269215520914067. Epub 2020 Apr 20. The Effects of a Supportive-Educational Intervention on Women With Type 2 Diabetes and Diabetic Peripheral Neuropathy: A Randomized Controlled Trial , , , Affiliations Expand Affiliations 1 Bohlool Hospital, Gonabad University of Medical Sciences

2020 EvidenceUpdates

6. A pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from real-world experience Full Text available with Trip Pro

A pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from real-world experience A Pragmatic Study of Mid-Mixture Insulin and Basal Insulin Treatment in Patients With Type 2 Diabetes Uncontrolled With Oral Antihyperglycaemic Medications: A Lesson From Real-World Experience - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Apr 8. doi: 10.1111/dom.14052. Online ahead of print. A Pragmatic Study of Mid-Mixture Insulin and Basal Insulin Treatment in Patients With Type 2 Diabetes Uncontrolled With Oral Antihyperglycaemic Medications: A Lesson

2020 EvidenceUpdates

7. Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB) Full Text available with Trip Pro

Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB) Comparison of Tofogliflozin Versus Glimepiride as the Third Oral Agent Added to Metformin Plus a Dipeptidyl peptidase-4 Inhibitor in Japanese Patients With Type 2 Diabetes: A Randomized, 24-week, Open-Label, Controlled Trial (STOP-OB) - PubMed This site needs (...) to Metformin Plus a Dipeptidyl peptidase-4 Inhibitor in Japanese Patients With Type 2 Diabetes: A Randomized, 24-week, Open-Label, Controlled Trial (STOP-OB) , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. 2 Seino Internal Medicine Clinic, Koriyama, Japan. 3 Internal Medicine, Oyama East Clinic, Oyama, Japan. 4 Department

2020 EvidenceUpdates

8. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial Full Text available with Trip Pro

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial Long-term Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (The DEPICT-2 Study): 52-week Results From a Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Apr 20. doi: 10.1111/dom.14060. Online ahead of print. Long-term Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (The DEPICT-2 Study): 52-week Results From a Randomized Controlled Trial

2020 EvidenceUpdates

9. Effects of an Electronic Software Prompt With Health Care Professional Training on Cardiovascular and Renal Complications in a Multiethnic Population With Type 2 Diabetes and Microalbuminuria (the GP-Prompt Study): Results of a Pragmatic Cluster-Randomize

Effects of an Electronic Software Prompt With Health Care Professional Training on Cardiovascular and Renal Complications in a Multiethnic Population With Type 2 Diabetes and Microalbuminuria (the GP-Prompt Study): Results of a Pragmatic Cluster-Randomize Effects of an Electronic Software "Prompt" With Health Care Professional Training on Cardiovascular and Renal Complications in a Multiethnic Population With Type 2 Diabetes and Microalbuminuria (The GP-Prompt Study): Results of a Pragmatic (...) Software "Prompt" With Health Care Professional Training on Cardiovascular and Renal Complications in a Multiethnic Population With Type 2 Diabetes and Microalbuminuria (The GP-Prompt Study): Results of a Pragmatic Cluster-Randomized Trial , , , , , , , Affiliations Expand Affiliations 1 Diabetes Research Centre, University of Leicester, Leicester, U.K. 2 National Institute for Health Research Applied Research Collaboration (ARC) East Midlands, Leicester, U.K. 3 George Eliot Hospital National Health

2020 EvidenceUpdates

10. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Full Text available with Trip Pro

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Dose-response, Efficacy, and Safety of Oral Semaglutide Monotherapy in Japanese Patients With Type 2 Diabetes (PIONEER 9): A 52-week, Phase 2/3a, Randomised, Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Lancet Diabetes Endocrinol Actions . 2020 May;8(5):377-391. doi: 10.1016/S2213-8587(20)30075-9. Dose-response, Efficacy, and Safety of Oral Semaglutide Monotherapy in Japanese Patients With Type 2 Diabetes (PIONEER 9): A 52-week, Phase 2/3a, Randomised, Controlled Trial

2020 EvidenceUpdates

11. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial Safety and Efficacy of Oral Semaglutide Versus Dulaglutide in Japanese Patients With Type 2 Diabetes (PIONEER 10): An Open-Label, Randomised, Active-Controlled, Phase 3a Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Lancet Diabetes Endocrinol Actions . 2020 May;8(5):392-406. doi: 10.1016/S2213-8587(20)30074-7. Safety and Efficacy of Oral Semaglutide Versus Dulaglutide in Japanese Patients With Type 2 Diabetes (PIONEER 10): An Open-Label, Randomised, Active-Controlled, Phase 3a Trial

2020 EvidenceUpdates

12. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study Full Text available with Trip Pro

Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study Use of Sodium-Glucose cotransporter-2 Inhibitors and Risk of Acute Kidney Injury in Older Adults With Diabetes: A Population-Based Cohort Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation CMAJ Actions . 2020 Apr 6;192(14):E351-E360. doi: 10.1503/cmaj.191283. Epub 2020 Apr 5. Use of Sodium-Glucose cotransporter-2 Inhibitors and Risk of Acute Kidney Injury in Older Adults With Diabetes: A Population-Based Cohort Study , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Departments of Epidemiology and Biostatistics

2020 EvidenceUpdates

13. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study

Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health (...) Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul;43(7):1553-1556. doi: 10.2337/dc19-1944. Epub 2020 Apr 28. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Endocrinology, Department of Pediatrics, The Hospital

2020 EvidenceUpdates

14. Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study Full Text available with Trip Pro

Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Apr 28;dc192116. doi: 10.2337/dc19-2116. Online ahead of print. Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study , , , , , , , , , , Affiliations Expand Affiliations

2020 EvidenceUpdates

15. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study

Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study Safety of Dapagliflozin in a Broad Population of Patients With Type 2 Diabetes: Analyses From the DECLARE-TIMI 58 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National (...) : Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Apr 2. doi: 10.1111/dom.14041. Online ahead of print. Safety of Dapagliflozin in a Broad Population of Patients With Type 2 Diabetes: Analyses From the DECLARE-TIMI 58 Study , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Diabetes Unit, Department of Endocinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem

2020 EvidenceUpdates

16. ABCD position statement on standards of care for management of adults with type 1 diabetes

ABCD position statement on standards of care for management of adults with type 1 diabetes Standards of Care for Management of Adults with Type 1 Diabetes | ABCD (Diabetes Care) Ltd You are here: Standards of Care for Management of Adults with Type 1 Diabetes 2020 ABCD Standards of care for the management of adults with type 1 diabetes provides comprehensive standards for units providing care to people with type 1 diabetes and is intended as a resource for specialist teams. A summary document (...) is also available which includes a short summary of the recommendations from each section. The sections on inpatient care and management of diabetic emergencies are particularly relevant today. We are grateful to all the contributors. Discipline: Diabetes Clinical taxonomy: Type 1 diabetes mellitus Resource taxonomy: Guidelines Position Paper Information for HCPs Follow Us Address for correspondence: ABCD (Diabetes Care) Ltd, Miria House, 1683b High Street, Knowle, Solihull, West Midlands, B93 0LL

2020 Association of British Clinical Diabetologists

17. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. Full Text available with Trip Pro

Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. To estimate and compare progression rates to type 2 diabetes mellitus (T2DM) in women with gestational diabetes mellitus (GDM) and healthy controls.Systematic review and meta-analysis.Medline and Embase between January 2000 and December 2019, studies published in English and conducted on humans.Observational studies investigating progression to T2DM. Inclusion criteria were (...) postpartum follow-up for at least 12 months, incident physician based diagnosis of diabetes, T2DM reported as a separate outcome rather than combined with impaired fasting glucose or impaired glucose tolerance, and studies with both a group of patients with GDM and a control group.This meta-analysis of 20 studies assessed a total of 1 332 373 individuals (67 956 women with GDM and 1 264 417 controls). Data were pooled by random effects meta-analysis models, and heterogeneity was assessed by use of the I2

2020 BMJ

18. Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality

Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality Prescrire IN ENGLISH - Spotlight '' Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality'', 1 May 2020 {1} {1} {1} | | > > > Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |    (...) |   |   |   |   |   |   |   |  Spotlight In the May issue of Prescrire International: Dulaglutide (Trulicity°) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality FREE DOWNLOAD In patients with type 2 diabetes who had a modest elevation of HbA1c, a recent trial suggested that addition of dulaglutide to hypoglycaemic therapy slightly reduced the risk of stroke, but did not reduce either all-cause mortality

2020 Prescrire

19. Management of Hypoglycaemia in Children and Young People with Type 1 Diabetes

and caregivers, especially when there is a high risk of severe hypoglycaemia. Education on administration of glucagon is essential Blood glucose monitoring should be performed prior to exercise, and extra carbohydrates should be consumed based on the blood glucose level and the expected intensity and duration of the exercise REFERENCE 1. NICE (2015) Diabetes (type 1 and type 2) in children and young people. NICE guideline NG18 www.nice.org.uk/guidance/ng18 2. ISPAD Clinical Practice Consensus Guidelines 2014 (...) Management of Hypoglycaemia in Children and Young People with Type 1 Diabetes ssociation of Children’s Diabetes Clinicians Clinicians Version 4, May 2018 Review 2021 Authors: SM Ng, E Williams, F Ackland, C Burren, J Edge, E Hind, A McAulay, Bill Lamb 1 SETTING Children and young people with diabetes mellitus PATIENTS Children and young people with diabetes mellitus Guidance • Definition of hypoglycaemia in children with diabetes is a blood glucose 4.0mmol/L, Retest 20-30 minutes later

2020 British Society for Paediatric Endocrinology and Diabetes

20. Care of the Well Child-Newly Diagnosed with Type 1 Diabetes

published ahead of print September 6, 2012, doi:10.2337/dc12-0720 15. Canadian Agency for Drugs and Technologies in Health. Systematic review of use of blood glucose test strips for the management of diabetes mellitus. [June 2010]. Available from.www.cadth.ca/products/cadth-overviews/vol-1.../vol-1-issue-1-01 16. NICE (2015) Diabetes (type 1 and type 2) in children and young people. NICE guideline NG18 www.nice.org.uk/guidance/ng18 Version 4, Dec 2019 Review 2022 Authors: J Chizo Agwu, SM Ng, A Timmis (...) care in children at diagnosis of tyoe 1 diabetes mellitus. Cochrane Database of systematic reviews2007, issue 2. Art No: CD004099. DOI: 10.1002/14651858.CD004009.pub 2 19. Home based care improved glycaemic control and was cost effective in children with type 1 diabetes. Dougherty G, Schriffin A, White D, et al. Pediatrics 1999 Jan; 103: 122-8. 20. The delivery of ambulatory diabetes care to children and adolescents with diabetes. Pihoker C, Forsander G, Wolfsdorf J, Klingensmith GJ. Pediatric

2020 British Society for Paediatric Endocrinology and Diabetes